

Baik Lin Seong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5889617/publications.pdf>

Version: 2024-02-01

112
papers

3,064
citations

159358

30
h-index

197535

49
g-index

114
all docs

114
docs citations

114
times ranked

4427
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-Permeable and Biocompatible Polymeric Nanoparticles for Apoptosis Imaging. <i>Journal of the American Chemical Society</i> , 2006, 128, 3490-3491.	6.6	237
2	Type I Interferon Signaling Regulates Ly6Chi Monocytes and Neutrophils during Acute Viral Pneumonia in Mice. <i>PLoS Pathogens</i> , 2011, 7, e1001304.	2.1	186
3	Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. <i>EMBO Journal</i> , 2003, 22, 2104-2116.	3.5	120
4	MyD88 Signaling Is Indispensable for Primary Influenza A Virus Infection but Dispensable for Secondary Infection. <i>Journal of Virology</i> , 2010, 84, 12713-12722.	1.5	82
5	Chaperona-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles. <i>Frontiers in Immunology</i> , 2018, 9, 1093.	2.2	82
6	Design and Biological Evaluation of Novel Tubulin Inhibitors as Antimitotic Agents Using a Pharmacophore Binding Model with Tubulin. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5664-5670.	2.9	76
7	Prophylactic and Therapeutic Efficacy of Avian Antibodies Against Influenza Virus H5N1 and H1N1 in Mice. <i>PLoS ONE</i> , 2010, 5, e10152.	1.1	68
8	Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. <i>PLoS ONE</i> , 2011, 6, e27953.	1.1	66
9	Recombinant enterokinase light chain with affinity tag: Expression from <i>Saccharomyces cerevisiae</i> and its utilities in fusion protein technology. <i>Biotechnology and Bioengineering</i> , 2001, 75, 718-724.	1.7	63
10	Protein Solubility and Folding Enhancement by Interaction with RNA. <i>PLoS ONE</i> , 2008, 3, e2677.	1.1	63
11	Tea catechins as a potential alternative anti-infectious agent. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 497-506.	2.0	62
12	Exploiting virus-like particles as innovative vaccines against emerging viral infections. <i>Journal of Microbiology</i> , 2017, 55, 220-230.	1.3	59
13	Evaluation of green tea extract as a safe personal hygiene against viral infections. <i>Journal of Biological Engineering</i> , 2018, 12, 1.	2.0	59
14	Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. <i>Antiviral Research</i> , 2007, 76, 178-185.	1.9	57
15	RNA-mediated chaperone type for de novo protein folding. <i>RNA Biology</i> , 2009, 6, 21-24.	1.5	57
16	Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5'UTR of <i>TRIM22</i> . <i>Gut</i> , 2018, 67, 166-178.	6.1	56
17	Extracellular zinc stimulates ERK-dependent activation of p21Cip/WAF1 and inhibits proliferation of colorectal cancer cells. <i>British Journal of Pharmacology</i> , 2002, 137, 597-607.	2.7	55
18	Peptide amidation: Production of peptide hormones in vivo and in vitro. <i>Biotechnology and Bioprocess Engineering</i> , 2001, 6, 244-251.	1.4	51

#	ARTICLE	IF	CITATIONS
19	The Quest for a Truly Universal Influenza Vaccine. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 344.	1.8	51
20	Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms. <i>Frontiers in Microbiology</i> , 2020, 11, 1927.	1.5	43
21	RPS3a Over-Expressed in HBV-Associated Hepatocellular Carcinoma Enhances the HBx-Induced NF- κ B Signaling via Its Novel Chaperoning Function. <i>PLoS ONE</i> , 2011, 6, e22258.	1.1	42
22	Cold-Adapted Pandemic 2009 H1N1 Influenza Virus Live Vaccine Elicits Cross-Reactive Immune Responses against Seasonal and H5 Influenza A Viruses. <i>Journal of Virology</i> , 2012, 86, 5953-5958.	1.5	42
23	Options and Obstacles for Designing a Universal Influenza Vaccine. <i>Viruses</i> , 2014, 6, 3159-3180.	1.5	40
24	Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. <i>Frontiers in Microbiology</i> , 2018, 9, 83.	1.5	40
25	Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator. <i>Hepatology</i> , 2013, 58, 762-776.	3.6	39
26	N-terminal domains of native multidomain proteins have the potential to assist de novo folding of their downstream domains in vivo by acting as solubility enhancers. <i>Protein Science</i> , 2007, 16, 635-643.	3.1	38
27	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. <i>Journal of Medical Virology</i> , 2003, 71, 367-375.	2.5	35
28	Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs. <i>Viruses</i> , 2018, 10, 183.	1.5	35
29	Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. <i>Nature Communications</i> , 2019, 10, 185.	5.8	35
30	Comparison of Two Reconstituted Systems for In Vitro Transcription and Replication of Influenza Virus1. <i>Journal of Biochemistry</i> , 1992, 111, 496-499.	0.9	31
31	Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2975-2982.	1.4	31
32	Intranasal Adenovirus-Vectored Vaccine for Induction of Long-Lasting Humoral Immunity-Mediated Broad Protection against Influenza in Mice. <i>Journal of Virology</i> , 2014, 88, 9693-9703.	1.5	31
33	Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 153-168.	2.5	31
34	Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. <i>Vaccine</i> , 2006, 24, 1966-1974.	1.7	30
35	Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines. <i>Yonsei Medical Journal</i> , 2013, 54, 271.	0.9	30
36	Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine. <i>Vaccine</i> , 2007, 25, 8067-8076.	1.7	28

#	ARTICLE	IF	CITATIONS
37	Enhanced secretion of human granulocyte colony-stimulating factor directed by a novel hybrid fusion peptide from recombinant <i>Saccharomyces cerevisiae</i> at high cell concentration. , 1998, 57, 600-609.		27
38	The folding competence of HIV-1 Tat mediated by interaction with TAR RNA. <i>RNA Biology</i> , 2017, 14, 926-937.	1.5	27
39	Structure of influenza virus panhandle RNA studied by NMR spectroscopy and molecular modeling. <i>Nucleic Acids Research</i> , 1999, 27, 1392-1397.	6.5	26
40	Identification and Use of Zinc Finger Transcription Factors That Increase Production of Recombinant Proteins in Yeast and Mammalian Cells. <i>Biotechnology Progress</i> , 2008, 21, 664-670.	1.3	26
41	M1 RNA is important for the in-cell solubility of its cognate C5 protein: Implications for RNA-mediated protein folding. <i>RNA Biology</i> , 2015, 12, 1198-1208.	1.5	26
42	Co-degradation of interferon signaling factor DDX3 by PB1 as a basis for high virulence of 1918 pandemic influenza. <i>EMBO Journal</i> , 2019, 38, .	3.5	26
43	Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cells. <i>Antiviral Research</i> , 2019, 163, 11-18.	1.9	25
44	The production of 6-aminopenicillanic acid by a multistage tubular reactor packed with immobilized penicillin amidase. <i>Biotechnology and Bioengineering</i> , 1982, 24, 1623-1637.	1.7	24
45	Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity. <i>PLoS ONE</i> , 2015, 10, e0137608.	1.1	24
46	Microbial transformation of rifamycin B: A new synthetic approach to rifamycin derivatives.. <i>Journal of Antibiotics</i> , 1983, 36, 1402-1404.	1.0	23
47	Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea. <i>Veterinary Microbiology</i> , 2008, 130, 268-276.	0.8	21
48	Reverse genetic platform for inactivated and live-attenuated influenza vaccine. <i>Experimental and Molecular Medicine</i> , 2010, 42, 116.	3.2	21
49	Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1139-1152.	2.5	20
50	Harnessing an RNA-mediated chaperone for the assembly of influenza hemagglutinin in an immunologically relevant conformation. <i>FASEB Journal</i> , 2018, 32, 2658-2675.	0.2	20
51	Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay. <i>Vaccine</i> , 2019, 37, 1457-1466.	1.7	20
52	Characterization of HLA-A2.1-restricted epitopes, conserved in both Hantaan and Sin Nombre viruses, in Hantaan virus-infected patients. <i>Journal of General Virology</i> , 2002, 83, 1131-1136.	1.3	20
53	A FACILE PREPARATION OF RIFAMYCIN DERIVATIVES BY USE OF MANGANESE DIOXIDE. <i>Chemistry Letters</i> , 1982, 11, 627-628.	0.7	19
54	Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains. <i>Vaccine</i> , 2014, 32, 535-543.	1.7	17

#	ARTICLE	IF	CITATIONS
55	Protein Folding In Vivo Revisited. <i>Current Protein and Peptide Science</i> , 2013, 14, 721-733.	0.7	17
56	Novel Secretion System of Recombinant <i>Saccharomyces cerevisiae</i> Using an N-terminus Residue of Human IL-1 β as Secretion Enhancer. <i>Biotechnology Progress</i> , 1999, 15, 884-890.	1.3	16
57	5S rRNA-assisted DnaK refolding. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1177-1181.	1.0	16
58	Effect of mass transfer in a recirculation batch reactor system for immobilized penicillin amidase. <i>Biotechnology and Bioengineering</i> , 1982, 24, 2215-2226.	1.7	15
59	The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. <i>Biomaterials</i> , 2013, 34, 6261-6271.	5.7	15
60	Engineered Recombinant Enteropeptidase Catalytic Subunit: Effect of N-Terminal Modification. <i>Archives of Biochemistry and Biophysics</i> , 2002, 400, 1-6.	1.4	14
61	Investigation of Antigen Delivery Route in Vivo and Immune-Boosting Effects Mediated by pH-Sensitive Liposomes Encapsulated with Kb-Restricted CTL Epitope. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 682-688.	1.0	14
62	Chaperoning Roles of Macromolecules Interacting with Proteins in Vivo. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1979-1990.	1.8	14
63	Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 411-426.	2.5	14
64	Host Defense Mechanism-Based Rational Design of Live Vaccine. <i>PLoS ONE</i> , 2013, 8, e75043.	1.1	14
65	Purification of antibody fragments for the reduction of charge variants using cation exchange chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1080, 20-26.	1.2	14
66	Assessment of substrate-stabilizing factors for DnaK on the folding of aggregation-prone proteins. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 74-79.	1.0	13
67	Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets. <i>Vaccine</i> , 2013, 31, 1320-1327.	1.7	13
68	Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain. <i>Vaccine</i> , 2016, 34, 1343-1349.	1.7	13
69	RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform. <i>Biomaterials</i> , 2021, 269, 120650.	5.7	13
70	A multiplex RT-PCR method for screening of reassortant live influenza vaccine virus strains. <i>Journal of Virological Methods</i> , 2006, 134, 154-163.	1.0	12
71	Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. <i>Vaccine</i> , 2013, 31, 3339-3346.	1.7	12
72	Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. <i>Vaccine</i> , 2019, 37, 4987-4995.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant. <i>Frontiers in Immunology</i> , 2021, 12, 769088.	2.2	12
74	High-yield soluble expression of recombinant influenza virus antigens from <i>Escherichia coli</i> and their potential uses in diagnosis. <i>Journal of Virological Methods</i> , 2014, 196, 56-64.	1.0	11
75	Nucleic Acid-Dependent Structural Transition of the Intrinsically Disordered N-Terminal Appended Domain of Human Lysyl-tRNA Synthetase. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3016.	1.8	11
76	Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. <i>Frontiers in Immunology</i> , 2018, 9, 116.	2.2	11
77	Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses. <i>Vaccines</i> , 2021, 9, 353.	2.1	11
78	Inactivation of H1N1 viruses exposed to acidic ozone water. <i>Applied Physics Letters</i> , 2009, 95, 173704.	1.5	10
79	Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1441-1455.	2.5	10
80	Filamentous anti-influenza agents wrapping around viruses. <i>Journal of Colloid and Interface Science</i> , 2021, 583, 267-278.	5.0	10
81	Genotyping and screening of reassortant live-attenuated influenza B vaccine strain. <i>Journal of Virological Methods</i> , 2010, 165, 133-138.	1.0	9
82	Macromolecule-Assisted de novo Protein Folding. <i>International Journal of Molecular Sciences</i> , 2012, 13, 10368-10386.	1.8	9
83	Green Tea Catechin-Inactivated Viral Vaccine Platform. <i>Frontiers in Microbiology</i> , 2017, 8, 2469.	1.5	9
84	Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus. <i>Microbiology and Immunology</i> , 2018, 62, 574-584.	0.7	9
85	Chaperona: linking the ancient RNA and protein worlds. <i>RNA Biology</i> , 2021, 18, 16-23.	1.5	9
86	Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice. <i>PLoS ONE</i> , 2016, 11, e0152485.	1.1	9
87	RNA-dependent chaperone (chaperona) as an engineered pro-region for the folding of recombinant microbial transglutaminase. <i>Biotechnology and Bioengineering</i> , 2019, 116, 490-502.	1.7	8
88	Toward a universal influenza vaccine: from the perspective of protective efficacy. <i>Clinical and Experimental Vaccine Research</i> , 2013, 2, 71.	1.1	7
89	Highly chromophoric Cy5-methionine for N-terminal fluorescent tagging of proteins in eukaryotic translation systems. <i>Scientific Reports</i> , 2017, 7, 11642.	1.6	7
90	Recombinant adenylate kinase 3 from liver fluke <i>Clonorchis sinensis</i> for histochemical analysis and serodiagnosis of clonorchiasis. <i>Parasitology</i> , 2018, 145, 1531-1539.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Quality Screening of Incorrectly Folded Soluble Aggregates from Functional Recombinant Proteins. <i>International Journal of Molecular Sciences</i> , 2019, 20, 907.	1.8	7
92	Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies. <i>Scientific Reports</i> , 2019, 9, 19675.	1.6	7
93	N-Glycosylation of secretion enhancer peptide as influencing factor for the secretion of target proteins from <i>Saccharomyces cerevisiae</i> . <i>Biochemical and Biophysical Research Communications</i> , 2005, 337, 557-562.	1.0	6
94	Conversion of a soluble protein into a potent chaperone in vivo. <i>Scientific Reports</i> , 2019, 9, 2735.	1.6	6
95	Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin. <i>Virology</i> , 2016, 491, 1-9.	1.1	5
96	Stabilization of Intrinsically Disordered DKK2 Protein by Fusion to RNA-Binding Domain. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2847.	1.8	5
97	Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barré Syndrome. <i>Vaccines</i> , 2020, 8, 101.	2.1	5
98	Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts. <i>Biotechnology and Bioengineering</i> , 2020, 117, 1990-2007.	1.7	5
99	RNA-binding as chaperones of DNA binding proteins from starved cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 484-489.	1.0	5
100	A Conceptual Framework for Integrating Cellular Protein Folding, Misfolding and Aggregation. <i>Life</i> , 2021, 11, 605.	1.1	4
101	RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102438.	1.7	4
102	Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens. <i>FASEB Journal</i> , 2018, 32, 4658-4669.	0.2	3
103	Bead based facile assay for sensitive quantification of native state green fluorescent protein. <i>RSC Advances</i> , 2020, 10, 13095-13099.	1.7	3
104	A social distancing measure governing the whole proteome. <i>Current Opinion in Structural Biology</i> , 2021, 66, 104-111.	2.6	3
105	Production and characterization of active hepatitis C virus RNA-dependent RNA polymerase. <i>Protein Expression and Purification</i> , 2010, 71, 147-152.	0.6	2
106	Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine. <i>Virology</i> , 2017, 504, 73-78.	1.1	2
107	The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants. <i>Antiviral Research</i> , 2019, 168, 100-108.	1.9	2
108	A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 779223.	2.2	2

#	ARTICLE	IF	CITATIONS
109	Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes. <i>Virology</i> , 2022, 566, 143-152.	1.1	2
110	Current status for influenza control. <i>Biotechnology and Bioprocess Engineering</i> , 1999, 4, 157-164.	1.4	1
111	Toward a universal influenza vaccine: a retrospective. <i>Future Virology</i> , 2016, 11, 313-316.	0.9	1
112	Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process. <i>Archives of Pharmacal Research</i> , 2020, 43, 714-723.	2.7	0